NO20081435L - N-oksider som prodroger for piperazin- og piperidinderivater - Google Patents

N-oksider som prodroger for piperazin- og piperidinderivater

Info

Publication number
NO20081435L
NO20081435L NO20081435A NO20081435A NO20081435L NO 20081435 L NO20081435 L NO 20081435L NO 20081435 A NO20081435 A NO 20081435A NO 20081435 A NO20081435 A NO 20081435A NO 20081435 L NO20081435 L NO 20081435L
Authority
NO
Norway
Prior art keywords
art
relates
disease
manufacture
disclosed
Prior art date
Application number
NO20081435A
Other languages
English (en)
Norwegian (no)
Inventor
Gustaaf J M Van Scharrenburg
Roelof W Feenstra
Andrew C Mccreary
Mayke B Hesselink
Theodorus S M Koopman
Hendrik J Koster
Peter H Van Amsterdam
Marinus Verhage
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20081435L publication Critical patent/NO20081435L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20081435A 2005-08-22 2008-03-19 N-oksider som prodroger for piperazin- og piperidinderivater NO20081435L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70982105P 2005-08-22 2005-08-22
EP05107671 2005-08-22
PCT/EP2006/065477 WO2007023141A1 (en) 2005-08-22 2006-08-21 N-oxides as prodrugs of piperazine & piperidine derivatives

Publications (1)

Publication Number Publication Date
NO20081435L true NO20081435L (no) 2008-05-16

Family

ID=39246895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081435A NO20081435L (no) 2005-08-22 2008-03-19 N-oksider som prodroger for piperazin- og piperidinderivater

Country Status (17)

Country Link
EP (1) EP1919883B1 (de)
JP (1) JP2009504799A (de)
KR (1) KR20080046205A (de)
AT (1) ATE417834T1 (de)
AU (1) AU2006283882B2 (de)
CA (1) CA2621158A1 (de)
DE (1) DE602006004363D1 (de)
DK (1) DK1919883T3 (de)
ES (1) ES2318783T3 (de)
HR (1) HRP20090143T3 (de)
IL (1) IL188903A0 (de)
NO (1) NO20081435L (de)
PL (1) PL1919883T3 (de)
PT (1) PT1919883E (de)
RU (1) RU2394821C2 (de)
SI (1) SI1919883T1 (de)
WO (1) WO2007023141A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
JP2009539941A (ja) * 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Slv308およびl−dopaを含んでなる組み合わせ製剤
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
CA2661120A1 (en) 2006-08-31 2008-03-06 Solvay Pharmaceuticals B.V. Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物
MX2010007703A (es) * 2008-01-15 2010-09-14 Abbott Healthcare Products Bv Derivados de bifeprunox.
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
TWI579272B (zh) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶(pridopidine)之氫溴酸鹽
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE503170A (de) * 1975-09-02
JP3989554B2 (ja) * 1996-03-29 2007-10-10 デユフアー・インターナシヨナル・リサーチ・ベー・ブイ ピペラジンおよびピペリジン化合物
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
EP1283838B1 (de) * 2000-05-12 2003-12-03 Solvay Pharmaceuticals B.V. Piperazin- und piperidinverbindungen
US20050085510A1 (en) * 2002-01-16 2005-04-21 Telefonaktiebolaget Lm Ericsson (Publ) Prucalopride-n-oxide

Also Published As

Publication number Publication date
DE602006004363D1 (de) 2009-01-29
PL1919883T3 (pl) 2009-06-30
ATE417834T1 (de) 2009-01-15
DK1919883T3 (da) 2009-04-14
ES2318783T3 (es) 2009-05-01
CA2621158A1 (en) 2007-03-01
EP1919883A1 (de) 2008-05-14
SI1919883T1 (sl) 2009-04-30
IL188903A0 (en) 2008-04-13
AU2006283882B2 (en) 2011-06-23
RU2394821C2 (ru) 2010-07-20
EP1919883B1 (de) 2008-12-17
RU2008110945A (ru) 2009-09-27
WO2007023141A1 (en) 2007-03-01
JP2009504799A (ja) 2009-02-05
KR20080046205A (ko) 2008-05-26
AU2006283882A1 (en) 2007-03-01
PT1919883E (pt) 2009-03-26
HRP20090143T3 (hr) 2009-04-30

Similar Documents

Publication Publication Date Title
NO20081435L (no) N-oksider som prodroger for piperazin- og piperidinderivater
NO20051826L (no) Heterosyklisk substituerte piperaziner for behandling av schizofreni
MY141229A (en) Piperidine-benzenesulfonamide derivatives
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
BRPI0709773B8 (pt) derivados de malonamida, processo de produção do mesmo, medicamento, e seus usos como inibidores de gama-secretase no tratamento do mal de alzheimer
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
ATE493407T1 (de) 3-(heteroaryloxy)-2-alkyl-1- azabicycloalkylderivate als alpha.7-nachr- liganden zur behandlung von zns-erkrankungen
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
NO20064282L (no) Morfolinforbindelser
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
IL186777A0 (en) (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor
NO20083349L (no) Anvendelse av 2-imidazoler for behandling av CNS sykdommer
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni
GB0412314D0 (en) Compounds
ATE548367T1 (de) Dibenzoäb,füä1,4üoxazapinverbindungen
CO5640133A2 (es) Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de la serotonina
TW200738656A (en) N-oxides as prodrugs of piperazine and piperidine derivatives
ATE496534T1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
EA200870492A1 (ru) N-оксиды производных пиридилметилпиперазина и - пиперидина
MXPA05010678A (es) Derivados de 4-(2-fenilsulfanil-fenil)-1,2,3,6-tetrahidropiridina como inhibidores de recaptacion de serotonina.
DE602004025935D1 (de) Histondeacetylaseinhibitor und verfahren zu dessen herstellung
ATE334980T1 (de) Verfahren zur herstellung von 2-methyl piperazine derivaten.
IL188109A0 (en) Chloro-substituted guanidines

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application